Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Return on Capital Employed (2021 - 2023)

Cullinan Therapeutics has reported Return on Capital Employed over the past 3 years, most recently at 0.37% for Q3 2023.

  • Quarterly results put Return on Capital Employed at 0.37% for Q3 2023, down 60.0% from a year ago — trailing twelve months through Sep 2023 was 0.37% (down 60.0% YoY), and the annual figure for FY2022 was 0.3%, up 52.0%.
  • Return on Capital Employed for Q3 2023 was 0.37% at Cullinan Therapeutics, down from 0.33% in the prior quarter.
  • Over the last five years, Return on Capital Employed for CGEM hit a ceiling of 0.31% in Q2 2022 and a floor of 0.37% in Q3 2023.
  • Median Return on Capital Employed over the past 3 years was 0.14% (2021), compared with a mean of 0.04%.
  • Peak annual rise in Return on Capital Employed hit 47bps in 2023, while the deepest fall reached -64bps in 2023.
  • Cullinan Therapeutics' Return on Capital Employed stood at 0.16% in 2021, then soared by 263bps to 0.26% in 2022, then plummeted by -244bps to 0.37% in 2023.
  • The last three reported values for Return on Capital Employed were 0.37% (Q3 2023), 0.33% (Q2 2023), and 0.22% (Q1 2023) per Business Quant data.